About Us
The Team
The core of ZuriMED is built by its people. Our interdisciplinary and diverse team is backed by a strong board of directors comprised of world-renowned experts. Together, we aim to push the boundaries of current orthopedic and sports medicine solutions through our innovative technologies.
Peter Pan
Marketing Manager
Our Board of Directors is comprised of world-leading scientists, consultants and clinicians supporting the company in their field of expertise.
Prof. Dr. Jess Snedeker
President of the Board of Directors
Ulrich Looser
Member of the Board of Directors
Tyler Beeson
Member of the Board of Directors
Dr. med. Dominique Tschudi
Vice President of the Board of Directors
Dr. Helen (Ying) Yang
Member of the Board of Directors
Dr. Xiang Li
Member of the Board of Directors
Prof. Dr. Robert Frigg
Member of the Board of Directors
Chan-Yuan Lu
Member of the Board of Directors
Join the Team!
Junior Event & Administration Manager
Junior Lifecycle Engineer
Get to Know Us
ZuriMED originated in Zurich, Switzerland, and is part of the Swiss health cluster. Surrounded by world-leading universities and orthopedic healthcare institutes, we have unique access to high-quality labs, clinical knowledge, and exceptionally skilled talents.
The startup spun off from the University of Zurich and ETH Zurich in 2015 and is supported by Balgrist Beteiligungs AG. With this, we benefit from a close collaboration with research groups and clinicians, accelerating the transition from bench to bedside.
Our Values
Innovation
We embrace creativity and entrepreneurial thinking, developing groundbreaking technologies to pioneer advancements and reshape the future of healthcare.
Ambition
Our relentless pursuit of excellence and our vision of improving patients’ lives drive us to set new benchmarks in the industry.
Reliability
We are committed to creating a working environment where employees can trust each other while delivering high-quality products and services that healthcare professionals as well as patients can rely on.
Our Mission
ZuriMED strives to develop innovative technologies that overcome current limitations in soft tissue repair by leveraging our pragmatic, agile, and motivated team in close collaboration with healthcare professionals.
Our Vision
We envision a future where our products have redefined modern surgical practices to maximize the quality of physicians’ treatment options and patients’ lives.
Sustainability
At ZuriMED, we are driven by the mission of sustainable innovation and guided by our vision for a better future — not only revolutionizing soft tissue repair in sports medicine but also fostering healthy competition in the MedTech industry while focusing on local environmental impact.
Our Sustainability Goal
Creating a fair workspace where diversity and inclusion are embraced, while focusing on local initiatives and partnerships. We not only take the well-being of our patients and employees seriously but also uphold our responsibility to local communities.
2025 | Market Launch
The 12th of February marks the day of the market entry of the FiberLocker System in the U.S. Since then, the reinforcement system is commercially available and can be used for rotator cuff augmentation in the clinical setting.
2024 | FiberLocker System receives FDA Clearance
In December 2024, ZuriMED Technologies AG celebrated a significant achievement: the FDA clearance of our 510(k) submission for the FiberLocker® System. This represents the first clinical indication of the pioneering Surgical-Fiberlock® technology. We anticipate a limited U.S. market release of the SpeedPatch® PET and FiberLocker® Instrument in early 2025, allowing patients to soon benefit from this new technology.
2023 | ZuriMED closes Series-A financing round & receives Innosuisse Swiss Accelerator Grant
The financing round was led by Chindex Medical Limited (Hong Kong), followed by Yellowstone Holding AG (Geneva) and a group of private investors that includes leading orthopaedic surgeons from Switzerland, Germany, France, and the United States. An additional non-diluting funding from Innosuisse will greatly expedite the development and regulatory registration process of a second clinical indication.
2022 | ZuriMED obtains Innosuisse Scale-up Award & Innosuisse Project Grant
Thanks to this award, ZuriMED can access the second phase of the Scale-up Coaching program to further accelerate the growth in Switzerland and the expansion into new global markets. The Project Grant supports the co-development with research partner University Hospital Balgrist on ZuriMED’s breakthrough technology for soft tissue repair.
2021 | ISO 13485 certificate obtained
ZuriMED achieves ISO 13485 certification through BSI
2020 | ZuriMED closes a license deal with an international medical device company
One of ZuriMED’s endocortical fixation technologies for soft tissue repair has been licensed to an international medical device company. A strategic partnership has been established to work together to bring this technology to clinical applications.
2019 | ZuriMED obtains the Innosuisse Certificate
The company has now obtained the Innosuisse certificate in recognition for the potential of its technology and solutions. The role of Innosuisse – the Swiss Innovation Agency – is to promote science-based innovation in the interests of industry and society in Switzerland.
2018 | Capital increase – loan conversion executed
Loan conversion of the seed round investment into equity.
2017 | Start of Innosuisse funded First-in-man study
Clinical trial on ZuriMED’s first product, the BTB-Converter™ was approved by Swissethics and sponsored by Innosuisse (formerly Commission for Technology and Innovation in Switzerland [CTI]).
2016 | Seed round investment received
Investment in terms of convertible loan. ZuriMED moves into the newly opened Balgrist Campus.
2015 | Incorporation of ZuriMED Technologies AG
Winner of Venture Kick Final, Switzerland’s largest start-up acceleration program. Presenting 2nd best business plan by >>venture>>, the leading competition for entrepreneurs in Switzerland, a joint initiative of ETH Zurich, McKinsey & Company, Knecht Holding, Innosuisse and EPFL.
BTB-Converter™
Knee ligament reconstruction
Eight years of advanced biomaterial research and translational development at the University and ETH Zürich, in collaboration with leading Swiss surgeons, has led to ZuriMED’s Bone-Tendon-Bone (BTB)-Converter™ for knee ligament reconstruction.
This technology was developed by ZuriMED in the past and has now been out-licensed.
